Extensive transmission of SARS-CoV-2 BQ.1* variant in a population with high levels of hybrid immunity : A prevalence survey
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved..
OBJECTIVES: The SARS-CoV-2 BQ.1* variant rapidly spread globally in late 2022, posing a challenge due to its increased immune evasion.
METHODS: We conducted a prevalence survey in Brazil from November 16 to December 22, 2022, as part of a cohort study. We conducted interviews and collected nasal samples for reverse transcription-polymerase chain reaction (RT-PCR) testing and whole-genome sequencing. Cumulative incidence was estimated using RT-PCR positivity, cycle threshold values, and external data on the dynamics of RT-PCR positivity following infection.
RESULTS: Among 535 participants, 54% had documented SARS-CoV-2 exposure before this outbreak and 74% had received COVID-19 vaccination. In this study, 14.8% tested positive for SARS-CoV-2, with BQ.1* identified in 90.7% of cases. Using case data and cycle threshold values, cumulative incidence was estimated at 56% (95% confidence interval, 36-88%). Of the 79 positive participants, 48.1% had a symptomatic illness, with a lower proportion fulfilling the World Health Organization COVID-19 case definition compared to prior Omicron waves. No participants required medical attention.
CONCLUSIONS: Despite high population-level hybrid immunity, the BQ.1* variant attacked 56% of our population. Lower disease severity was associated with BQ.1* compared to prior Omicron variants. Hybrid immunity may provide protection against future SARS-CoV-2 variants but in this case was not able to prevent widespread transmission.
| Errataetall: |
ErratumIn: Int J Infect Dis. 2024 Mar 6;141:106964. - PMID 38452689 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:139 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 139(2024) vom: 07. Feb., Seite 159-167 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aguilar Ticona, Juan P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BQ.1 variant |
|---|
| Anmerkungen: |
Date Completed 15.01.2024 Date Revised 12.03.2024 published: Print-Electronic ErratumIn: Int J Infect Dis. 2024 Mar 6;141:106964. - PMID 38452689 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2023.11.039 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365615145 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365615145 | ||
| 003 | DE-627 | ||
| 005 | 20240312233438.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2023.11.039 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM365615145 | ||
| 035 | |a (NLM)38070701 | ||
| 035 | |a (PII)S1201-9712(23)00801-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aguilar Ticona, Juan P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Extensive transmission of SARS-CoV-2 BQ.1* variant in a population with high levels of hybrid immunity |b A prevalence survey |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.01.2024 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Int J Infect Dis. 2024 Mar 6;141:106964. - PMID 38452689 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVES: The SARS-CoV-2 BQ.1* variant rapidly spread globally in late 2022, posing a challenge due to its increased immune evasion | ||
| 520 | |a METHODS: We conducted a prevalence survey in Brazil from November 16 to December 22, 2022, as part of a cohort study. We conducted interviews and collected nasal samples for reverse transcription-polymerase chain reaction (RT-PCR) testing and whole-genome sequencing. Cumulative incidence was estimated using RT-PCR positivity, cycle threshold values, and external data on the dynamics of RT-PCR positivity following infection | ||
| 520 | |a RESULTS: Among 535 participants, 54% had documented SARS-CoV-2 exposure before this outbreak and 74% had received COVID-19 vaccination. In this study, 14.8% tested positive for SARS-CoV-2, with BQ.1* identified in 90.7% of cases. Using case data and cycle threshold values, cumulative incidence was estimated at 56% (95% confidence interval, 36-88%). Of the 79 positive participants, 48.1% had a symptomatic illness, with a lower proportion fulfilling the World Health Organization COVID-19 case definition compared to prior Omicron waves. No participants required medical attention | ||
| 520 | |a CONCLUSIONS: Despite high population-level hybrid immunity, the BQ.1* variant attacked 56% of our population. Lower disease severity was associated with BQ.1* compared to prior Omicron variants. Hybrid immunity may provide protection against future SARS-CoV-2 variants but in this case was not able to prevent widespread transmission | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BQ.1 variant | |
| 650 | 4 | |a High incidence | |
| 650 | 4 | |a Hybrid immunity | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Xiao, Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Nery, Nivison |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Hitchings, Matt |e verfasserin |4 aut | |
| 700 | 1 | |a Belitardo, Emilia M M Andrade |e verfasserin |4 aut | |
| 700 | 1 | |a Fofana, Mariam O |e verfasserin |4 aut | |
| 700 | 1 | |a Victoriano, Renato |e verfasserin |4 aut | |
| 700 | 1 | |a Cruz, Jaqueline S |e verfasserin |4 aut | |
| 700 | 1 | |a de Moraes, Laise |e verfasserin |4 aut | |
| 700 | 1 | |a Strobel, Icaro Morais |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Jessica Jesus |e verfasserin |4 aut | |
| 700 | 1 | |a Sena do Aragão Filho, Ananias |e verfasserin |4 aut | |
| 700 | 1 | |a Ribeiro, Guilherme S |e verfasserin |4 aut | |
| 700 | 1 | |a Reis, Mitermayer G |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Khouri, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Ko, Albert I |e verfasserin |4 aut | |
| 700 | 1 | |a Cummings, Derek A T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 139(2024) vom: 07. Feb., Seite 159-167 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:139 |g year:2024 |g day:07 |g month:02 |g pages:159-167 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2023.11.039 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 139 |j 2024 |b 07 |c 02 |h 159-167 | ||